TLDR
- Shares of Vera Therapeutics increased 4% to $35.39 following the release of two-year ORIGIN3 trial results for Trutakna
- The kidney drug reduced disease progression to levels consistent with healthy aging in IgA nephropathy patients
- The company intends to submit a supplemental Biologics License Application during Q4 for complete FDA approval
- TD Cowen maintained its Buy recommendation with a price target of $78 after reviewing the data
- Despite Tuesday’s gain, VERA shares remain down 34% year-to-date amid competition from Vertex and Otsuka
Shares of Vera Therapeutics advanced 4% to reach $35.39 on Tuesday following the biotechnology company’s disclosure of two-year clinical trial data from its ORIGIN3 study evaluating Trutakna, offering encouragement to investors in a stock that has faced challenges throughout 2026.
The clinical study enrolled patients diagnosed with immunoglobulin A nephropathy, a kidney disease characterized by abnormal antibody deposits that impair the organ’s filtration capabilities. Data revealed that Trutakna reduced the rate of kidney function deterioration to levels comparable with natural aging, representing a critical threshold for therapeutic success.
The treatment achieved an annualized eGFR slope delta of +5.0 mL/min/year compared to placebo. Specifically, Trutakna produced a two-year annualized eGFR decline of merely -0.6 mL/min/year, aligning with rates observed in healthy individuals.
TD Cowen maintained its Buy rating and $78 price objective following the data release, characterizing the kidney function results as among the most impressive generated in any Phase 3 IgAN clinical trial to date.
This figure also exceeded the +4.5 mL/min/year placebo-adjusted benefit demonstrated by competing therapy Voyxact, although TD Cowen noted the variance might be attributed to standard measurement fluctuation.
Study participants also demonstrated improvement across critical disease indicators, including reduced protein spillage and blood presence in urine samples. Dr. Richard Lafayette, a Stanford nephrology professor serving as a trial investigator, stated the findings offer compelling evidence that Trutakna can diminish long-term risks of requiring dialysis, kidney transplantation, or mortality.
Path to Complete FDA Authorization
The FDA granted Trutakna accelerated approval this past July, based on demonstrated reductions in urinary protein levels. To secure full regulatory approval, Vera must now provide confirmatory evidence demonstrating sustained clinical advantages.
Management plans to submit a supplemental Biologics License Application during the fourth quarter. Chief Commercial Officer Matt Skelton reported that within the initial 10 weeks post-launch, the company recorded over 350 patient start forms and has begun receiving reimbursed insurance claims.
Wall Street price targets for the stock span from $34 to $100, with consensus sentiment categorized as Strong Buy. Raymond James continues recommending Strong Buy with an $84 price objective, while Goldman Sachs maintains a Buy rating with an $80 target after a modest reduction. H.C. Wainwright decreased its target to $90 from $125, referencing competitive trial results from an alternative treatment.
Market Competition Weighs on Performance
Notwithstanding Tuesday’s price appreciation, VERA shares have declined 34% since the beginning of the year, pressured by intense competition in the IgAN therapeutic landscape.
Otsuka introduced Voyxact in late 2025 via the accelerated approval pathway. Though both medications address the same condition, Voyxact inhibits a single protein target, whereas Trutakna acts on two separate protein pathways.
Vertex is advancing its own dual inhibitor candidate, povetacicept, which has received BLA acceptance for accelerated approval with a regulatory decision date set for November 30. Shares of competitor Vertex declined 1% on Tuesday.
The company maintains a balance sheet with cash reserves exceeding debt obligations, a financial position that both TD Cowen and InvestingPro identified as a significant strength for a clinical-stage biotechnology firm.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
